Animal Parasiticides Market Size, Share & Analysis Report, 2022-2030
According to Nova one advisor, the global Animal Parasiticides market size is expected to hit around USD 20.7 billion by 2030 from valued at USD 9.8 billion in 2021 and growing at a CAGR of 11.2% from 2022 to 2030.
Factors such as the rising demand for animal-derived food products, increasing investments by private players, growing concerns of zoonotic diseases, regulations for preventing the spread of animal diseases, growing companion animal ownership rates, and rising animal health expenditure are driving the growth of the animal parasiticides market. However, a shift toward vegetarianism and restrictions on the use of parasiticides in food-producing animals are expected to restrain the growth of this market during the forecast period.
Report Scope of the Animal Parasiticides Market
|
Report Coverage |
Details |
|
Market Size |
USD 20.7 Billion by 2030 |
|
Growth Rate |
CAGR of 11.2% from 2022 to 2030 |
|
Largest Market |
North America |
|
Fastest Growing Market |
Asia Pacific |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2030 |
|
Segments Covered |
By type, Animal type, End UserAnd Region |
|
Companies Mentioned |
Zoetis Inc. (US), Elanco Animal Health Incorporated (US), Virbac (France), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Ceva Santé Animale (France), Vetoquinol S.A. (France), PetIQ, Inc. (US), Norbrook (Ireland), and Bimeda Animal Health (US). |
Animal Parasiticides Market Dynamics:
DRIVERS
Rising demand for animal-derived food products
The livestock sector is a highly dynamic and significant global asset. The volume production of meat has increased from 318.2 million metric tons in 2016 to 3310.5 million metric tons in 2018 worldwide. Livestock products contribute 18% to kilocalorie consumption and 34% to protein consumption globally; however, this varies across developed and developing countries.
The demand for meat has grown over the last 50 years, while production has more than quadrupled globally. The world now produces more than 320 million tons of meat and 800 million tons of milk each year. This is mainly attributed to the rising demand for livestock products in developing countries. While high-income countries have shown a steady and consistent rise, the rising populations of emerging and developing markets have supported similar and explosive growth. Africa’s demand for livestock-derived foods is projected to increase by a remarkable 80% in just two decades (from 2010 to 2030), mostly due to its increasing population. In addition, the demand for livestock food products is expected to increase from 200 kcal per person per day in 2000 to around 400 kcal per person per day by 2050 in sub-Saharan Africa and South Asia.
Since diseases caused by endoparasites may prove fatal to animals, resulting in lower meat and milk production, there is a need to prevent the spread and infection caused by endoparasites among food-producing animals. This, coupled with the growing demand for animal protein worldwide, is expected to drive the growth of the parasiticides market in the coming years.
Increasing investments by private players
The animal health market has grown modestly in the past few years, largely driven by growing awareness and rising concerns over zoonotic diseases. This industry has attracted huge investments from leading market players, mainly due to the growing demand in the animal parasiticides market for effective drugs. This is one of the major drivers increasing R&D efforts in the animal health industry. At present, many leading market players are focusing on R&D to develop new drugs. Globally, spending on R&D in animal healthcare is about 7–8% of the total revenue of individual market players. According to the European International Federation of Animal Health, major players spend 13% of their annual sales on R&D activities, while 7% of annual sales are invested in R&D activities by small and medium players. Of the total R&D expenditure, around 36% is spent on defensive R&D to keep existing products in the market. For instance, Zoetis’ R&D expenditure on animal health has increased from USD 432 million in 2018 to USD 4 million in 2021.
Currently, many leading players in the animal health industry are broadening their research facilities to offer innovative solutions in the veterinary pharmaceutical market, including antiparasitics for animal welfare. Major market players are focusing on expanding their global footprints by establishing R&D centers and production facilities, acquiring regional market players, and agreements and partnerships in these high-growth markets. For instance, in August 2019, Elanco acquired Bayer’s Animal Health Business at USD 8.6 billion. This acquisition doubled Elanco’s companion animal business and advanced its portfolio mix by creating a balance between its food animal and companion animal segments.
RESTRAINTS:
Regulations restricting the use of parasiticides for food-producing animals
The use of parasiticides in livestock animals is subject to various federal regulations in many countries. The extra-label use of these topical parasiticides could leave residues that may, on consumption by human beings, have side effects. As a result, the use of these parasiticides, especially endoparasiticides, needs to be regulated; safe residue concentrations and withdrawal periods for antiparasitics used in food-producing animals must be standardized, and slaughtered animals need to be monitored for possible unsafe residues.
In the US, parasiticides given to food-producing animals have precise FDA-regulated withdrawal times (the time taken post drug administration for drug residues to reach limits set by the FDA) to prevent the presence of harmful drug residues. Similarly, according to the National Organic Program, parasiticides are banned for all organic slaughter stock. In the UK, the Veterinary Medicines Directorate’s non-statutory program, in cooperation with the National Surveillance Scheme, carries out residue analysis on imported and processed animal foods to ensure that authorized medicines, including parasiticides, are not present above the permitted level (known as the maximum residue limit) in food. In Canada, the Canadian Food Inspection Agency sets guidelines regarding withdrawal times for animal drugs, including parasiticides.
Shift towards vegetarianism
Globally, there is a significant rise in the prevalence of obesity and other chronic disorders. Owing to this, many people are shifting toward a vegetarian diet from a predominantly non-vegetarian diet. According to Google Trends, interest in veganism increased sevenfold between 2014 and 2021. The US Department of Agriculture releases dietary guidelines on a timely basis. These guidelines influence nutrition education, public policy, and food programs and provide guidance on food choices with recommendations for weight management and physical activity. In addition, these guidelines encourage the consumption of fruits and vegetables, whole grains, and low-fat milk and equivalents.
The vegan business is booming in the US, with plant-based food product sales totaling almost USD 4.5 billion, a 32.3% growth from 2017 to 2019. According to The Vegan Society reports, as of 2018, there were about 600,000 vegans in the UK (1.16% of the population)—a 300% jump from 2014 (150,000, or 0.25% of the population). Changing eating habits and increasing exposure to global cuisines are also driving the shift to vegetarian diets. This shift has reduced the demand for meat, animal proteins, and eggs, which directly hampers the growth of the livestock industry. In addition, the increasing number of bird flu and infections caused due to meat consumption, such as swine flu and COVID-19, has led to a decrease in meat consumption. This is expected to restrain the growth of dependent industries, such as the animal parasiticides industry, to a certain extent.
OPPORTUNITY:
Lucrative opportunities in emerging markets
Over the last few years, companion animal ownership has witnessed a steady increase, especially in emerging countries such as India, China, Brazil, and other APAC and Latin American countries. Rapid urbanization and growing disposable incomes are driving pet ownership in these countries. Many pet owners in these countries are now willing to spend more on pet care.
On the other hand, emerging countries like India and China have robust livestock markets. According to the National Dairy Development Board, milk production in India has increased every year—from 147.3 million tons in 2015 to 166.4 million tons in 2017 and 187.7 million tons in 2019. Moreover, India is the world’s largest milk producer, accounting for 19% of the global market. As of January 2020, China is the world’s largest pork producer, producing about 55 million metric tons of pork each year. Milk production and consumption in China are also increasing at a rapid pace.
The large poultry and dairy animal populations in emerging markets are expected to drive the growth of the veterinary health market, as poultry animals are more prone to parasitic diseases. This will also attract investments from global players to these markets. However, historically, the adoption of animal parasiticides in veterinary practices, livestock farms, and pet owners in these countries has been comparatively less than that in developed markets. According to the Food and Agriculture Organization, the livestock sector in Latin America has grown at an annual rate (3.7%) higher than the average global growth rate (2.9%). The number of pet animals in the region has increased from 165.9 million in 2018 to 182.3 million in 2021. With the surge in companion animal population, the growing demand for animal food products, the huge population of livestock animals, and the increasing animal health expenditure in emerging countries across the APAC and Latin America, these regions showcase high-growth opportunities for players in the animal parasiticides market.
CHALLENGES:
The stringent regulatory approval process for drugs
To ensure that animal parasiticides have no side effects on animal health and are of sufficient quality and efficacy, authorities have set stringent regulations to approve animal parasiticides.
The US FDA; Canadian Food Agency; European Medical Agency; Ministry of Agriculture, Forestry, and Fisheries (MAFF); and Australian Pesticides and Veterinary Medicines Authority (APVMA) are some major regulatory bodies that approve medicines used for veterinary purposes. The Veterinary International Committee for Harmonization (VICH) also plays a significant role in bringing together regulatory authorities in the US, Europe, and Japan; it also harmonizes guidelines and technical requirements to register veterinary products. These regulatory bodies have set stringent regulations to approve veterinary pharmaceutical products. Regulatory standards for the approval of new veterinary pharmaceutical products, including antimicrobials, antibiotics, vaccines, parasiticides, and other pharmaceutical products, are also very stringent in Australia, Japan, and China.
Typically, the approval of veterinary pharmaceuticals in the US and European markets may take up to 5–11 years (from product development to commercialization). Considering the time-consuming and expensive nature of the development and approval process of new veterinary pharmaceutical products, many market players are reluctant to invest in developing new variants of veterinary pharmaceuticals for emerging microorganisms and parasites.
Diversity in parasite species
The diversity of parasite species is a major concern while diagnosing the cause of illness in animals. The identification of the species is followed by developing a new drug for treating ailments caused by the same; this is a time-consuming process. Sometimes, an animal may be administered with an endoparasiticide that differs from the one designed for the diagnosed causative endoparasite. In such cases, the causative agent may develop immunity against the endoparasiticide. Therefore, manufacturers of parasiticides must conduct different tests on animals to prove the efficiency of the drug developed. This is a time-consuming and expensive task, which may lead to the disapproval of new drugs developed as parasiticides.
The vast diversity of parasite species is a challenge for this market because it becomes difficult for manufacturers to design a parasiticide to fight different parasites. This is compounded by the fact that each parasiticide takes 5–10 years to come into existence.
Ectoparasiticides segment accounted for the largest share in the animal parasiticides market.
Based on type, the animal parasiticides market is segmented into endoparasiticides, ectoparasiticides, and endectocides. The ectoparasiticides segment accounted for the largest share of 58.4% of the global animal parasiticides market in 2020. This segment is projected to reach USD 8,583.1 million by 2030 from USD 5,704.9 million in 2021, at a CAGR of 8.20%. The large share of this segment can be attributed to the higher adoption of ectoparasiticides as compared to other products. The increasing population of companion animals and rising pet ownership in developed countries are also expected to support the growth of this market during the forecast period.
Companion Animals segment is expected to witness the fastest growth in the forecast period.
Based on animal type, the animal parasiticides market is segmented into companion animals and livestock animals. In 2020, companion animals accounted for the largest share of 53.2% of the global animal parasiticides market. This segment is projected to reach USD 7,638.2 million by 2030 from USD 5,132.2 million in 2021, at a CAGR of 9.3%. The large share of this segment is primarily attributed to the increasing expenditure on pet animals and increasing companion animal ownership in developed countries.
Veterinary Clinics & Hospitals accounted for the largest share of animal parasiticides market in 2021”
Based on end users, the animal parasiticides market is segmented into veterinary clinics & hospitals, animal farms, and home care settings. Veterinary clinics & hospitals accounted for the largest share of 62.4% of the animal parasiticides market in 2020. This segment is projected to reach USD 8,255.7 million by 2030 from USD 5,956.6 million in 2021, at a CAGR of 7.8%. The large share of this segment can be attributed to the higher adoption of animal parasiticides in hospital settings, the increasing incidence of parasitic diseases, and growing awareness about animal health in developing countries.
North America accounted for the largest share of the animal parasiticides market in 2021
On the basis of region, the animal parasiticides market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of 42.3% of the global animal parasiticides market in 2021. This market is projected to reach USD 5,180.1 million by 2026 from USD 3,880.4 million in 2021, at a CAGR of 7.9%. The large share of North America is due to its well-established base of the animal health industry, the high adoption of companion animals, and the growing expenditure on animal health. The market in Latin America is expected to grow at the highest CAGR of 9.8% during the forecast period. This can be attributed to the growing population of livestock animals, increasing consumption of animal-derived food products, and growing adoption of pets.
Some of the prominent players in the Animal Parasiticides Market include:
Zoetis Inc. (US), Elanco Animal Health Incorporated (US), Virbac (France), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Ceva Santé Animale (France), Vetoquinol S.A. (France), PetIQ, Inc. (US), Norbrook (Ireland), and Bimeda Animal Health (Ireland).
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Animal Parasiticides market
By Type
By Animal Type
By End User
By Regional Outlook
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 32)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 ANIMAL PARASITICIDES MARKET SEGMENTATION
FIGURE 2 ANIMAL PARASITICIDES MARKET, BY REGION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 37)
2.1 RESEARCH APPROACH
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 4 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 8 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS INC.
FIGURE 10 COUNTRY-LEVEL ANALYSIS OF THE ANIMAL PARASITICIDES MARKET
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE ANIMAL PARASITICIDES MARKET (2021–2030): IMPACT ON MARKET GROWTH & CAGR
FIGURE 12 CAGR PROJECTIONS
FIGURE 13 TOP-DOWN APPROACH
2.3 LIMITATIONS
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 14 MARKET DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE ANALYSIS
2.6 ASSUMPTIONS FOR THE STUDY
2.7 RISK ASSESSMENT/LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 51)
FIGURE 15 ANIMAL PARASITICIDES MARKET, BY TYPE, 2021 VS. 2030
FIGURE 16 ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2021 VS. 2030
FIGURE 17 ANIMAL PARASITICIDES MARKET, BY END USER, 2021 VS. 2030
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE ANIMAL PARASITICIDES MARKET
4 PREMIUM INSIGHTS (Page No. - 54)
4.1 ANIMAL PARASITICIDES MARKET OVERVIEW
FIGURE 19 INCREASING INCIDENCE OF ZOONOTIC DISEASES AND PARASITIC INFECTIONS TO DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: ANIMAL PARASITICIDES MARKET, BY TYPE & COUNTRY (2020)
FIGURE 20 ECTOPARASITICIDES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC ANIMAL PARASITICIDES MARKET IN 2020
4.3 ANIMAL PARASITICIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
4.4 ANIMAL PARASITICIDES MARKET: GEOGRAPHIC MIX
FIGURE 22 NORTH AMERICA TO CONTINUE TO DOMINATE THE ANIMAL PARASITICIDES MARKET DURING THE FORECAST PERIOD
4.5 ANIMAL PARASITICIDES MARKET: DEVELOPING VS. DEVELOPED COUNTRIES
FIGURE 23 DEVELOPING COUNTRIES TO OFFER GROWTH OPPORTUNITIES FOR MARKET PLAYERS DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 58)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 24 ANIMAL PARASITICIDES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising demand for animal-derived food products
FIGURE 25 WORLD MILK PRODUCTION ESTIMATES (2021–2030)
FIGURE 26 WORLD MEAT PRODUCTION ESTIMATES (2021–2030)
5.2.1.2 Increasing investments by private players
5.2.1.3 Growing concerns of zoonotic diseases
5.2.1.4 Regulations for preventing the spread of animal diseases
5.2.1.5 Growing companion animal ownership rates
FIGURE 27 DEVELOPED COUNTRIES: PET POPULATION & PET OWNERSHIP
5.2.1.6 Growing prevalence of animal diseases
5.2.1.7 Rising animal health expenditure
FIGURE 28 INCREASING PET EXPENDITURE IN THE US, 2010–2022
FIGURE 29 EUROPE: ANNUAL VALUE OF PET-RELATED PRODUCTS (2010–2022)
5.2.2 RESTRAINTS
5.2.2.1 Regulations restricting the use of parasiticides for food-producing animals
5.2.2.2 Shift towards vegetarianism
5.2.2.3 Emerging novel drug development models
5.2.3 OPPORTUNITIES
5.2.3.1 Lucrative opportunities in emerging markets
5.2.4 CHALLENGES
5.2.4.1 Growing resistance to parasiticides
TABLE 1 PARASITICIDES & RESISTANT PARASITES
5.2.4.2 Stringent regulatory approval process for drugs
5.2.4.3 Diversity in parasite species
5.3 INDUSTRY TRENDS
5.3.1 GROWING CONSOLIDATION IN THE ANIMAL HEALTH INDUSTRY
TABLE 2 MAJOR ACQUISITIONS IN THE ANIMAL PARASITICIDES INDUSTRY(2018–2021)
5.3.2 INNOVATIONS IN ANIMAL PARASITICIDES
5.4 PORTER’S FIVE FORCES ANALYSIS
TABLE 4 PORTER’S FIVE FORCES ANALYSIS: ANIMAL PARASITICIDES MARKET (2020)
5.4.1 INTENSITY OF COMPETITIVE RIVALRY
5.4.2 BARGAINING POWER OF SUPPLIERS
5.4.3 BARGAINING POWER OF BUYERS
5.4.4 THREAT OF NEW ENTRANTS
5.4.5 THREAT OF SUBSTITUTES
5.5 REGULATORY ANALYSIS
FIGURE 30 DEVELOPMENT AND APPROVAL PROCESS FOR ANIMAL PARASITICIDES
FIGURE 31 APPROVAL PROCESS FOR ANIMAL PARASITICIDES IN EUROPE
5.6 PATENT ANALYSIS
FIGURE 32 PATENT ANALYSIS: ANIMAL PARASITICIDES MARKET(JANUARY 2011–AUGUST 2021)
5.7 ECOSYSTEM ANALYSIS
FIGURE 33 ECOSYSTEM ANALYSIS: ANIMAL PARASITICIDES MARKET
5.8 VALUE CHAIN ANALYSIS
FIGURE 34 VALUE CHAIN ANALYSIS: ANIMAL PARASITICIDES MARKET
5.9 SUPPLY CHAIN ANALYSIS
FIGURE 35 SUPPLY CHAIN ANALYSIS: ANIMAL PARASITICIDES MARKET
5.10 COVID-19 IMPACT ANALYSIS
5.10.1 COVID-19 HEALTH ASSESSMENT
5.10.2 COVID-19 ECONOMIC ASSESSMENT
5.10.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
FIGURE 36 CRITERIA IMPACTING THE GLOBAL ECONOMY
5.10.4 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE ANIMAL PARASITICIDES MARKET
FIGURE 37 COVID-19 IMPACT ON REGIONAL VETERINARY PRACTICE ACTIVITY (2020)
5.11 ADJACENT MARKET ANALYSIS
FIGURE 38 ANIMAL ANTIBIOTICS AND ANTIMICROBIALS MARKET: MARKET OVERVIEW
FIGURE 39 VETERINARY VACCINES MARKET: MARKET OVERVIEW
5.12 CASE STUDIES
FIGURE 40 CASE STUDY: MARKET ASSESSMENT FOR COMPANION ANIMALS
FIGURE 41 CASE STUDY: OPPORTUNITY ANALYSIS FOR BROAD-SPECTRUM PARASITICIDES
6 ANIMAL PARASITICIDES MARKET, BY TYPE (Page No. - 85)
6.1 INTRODUCTION
TABLE 5 ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
6.2 ECTOPARASITICIDES
TABLE 6 EXAMPLES OF ECTOPARASITICIDES AVAILABLE IN THE MARKET
TABLE 7 ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 8 ECTOPARASITICIDES MARKET, BY COUNTRY, 2022–2030
6.2.1 POUR-ONS & SPOT-ONS
6.2.1.1 Ease of application has supported the demand for pour-ons & spot-ons
TABLE 9 POUR-ONS & SPOT-ONS MARKET, BY COUNTRY, 2022–2030
6.2.2 ORAL TABLETS
6.2.2.1 High medication compliance and ease of administration are key growth drivers for this market
TABLE 10 ORAL TABLETS MARKET, BY COUNTRY, 2022–2030
6.2.3 SPRAYS
6.2.3.1 Low price and convenience to drive market growth
TABLE 11 SPRAYS MARKET, BY COUNTRY, 2022–2030
6.2.4 DIPS
6.2.4.1 The high popularity of dips has ensured sustained end-user demand
TABLE 12 DIPS MARKET, BY COUNTRY, 2022–2030
6.2.5 EAR TAGS
6.2.5.1 Ear tags are highly effective in controlling flies around cattle
TABLE 13 EAR TAGS MARKET, BY COUNTRY, 2022–2030
6.2.6 COLLARS
6.2.6.1 Growing prevalence of infections in companion animals to drive market growth
TABLE 14 COLLARS MARKET, BY COUNTRY, 2022–2030
6.2.7 OTHER ECTOPARASITICIDES
TABLE 15 OTHER ECTOPARASITICIDES MARKET, BY COUNTRY, 2022–2030
6.3 ENDOPARASITICIDES
TABLE 16 EXAMPLES OF ENDOPARASITICIDES AVAILABLE IN THE MARKET
TABLE 17 ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 18 ENDOPARASITICIDES MARKET, BY COUNTRY, 2022–2030
6.3.1 ORAL LIQUIDS
6.3.1.1 Growing demand for meat and milk products to drive market growth
TABLE 19 ORAL LIQUIDS MARKET, BY COUNTRY, 2022–2030
6.3.2 ORAL SOLIDS
6.3.2.1 Emergence of internal parasitic infections in dogs to drive the growth of the oral solids market
TABLE 20 ORAL SOLIDS MARKET, BY COUNTRY, 2022–2030
6.3.3 INJECTABLES
6.3.3.1 Injectables offer rapid results, which has supported their use
TABLE 21 INJECTABLES MARKET, BY COUNTRY, 2022–2030
6.3.4 FEED ADDITIVES
6.3.4.1 Feed additives can be administered to a large number of animals at once
TABLE 22 FEED ADDITIVES MARKET, BY COUNTRY, 2022–2030
6.3.5 OTHER ENDOPARASITICIDES
TABLE 23 OTHER ENDOPARASITICIDES MARKET, BY COUNTRY, 2022–2030
6.4 ENDECTOCIDES
TABLE 24 EXAMPLES OF ENDECTOCIDES AVAILABLE IN THE MARKET
TABLE 25 ENDECTOCIDES MARKET, BY COUNTRY, 2022–2030
7 ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE (Page No. - 105)
7.1 INTRODUCTION
TABLE 26 ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
7.2 COMPANION ANIMALS
TABLE 27 COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 28 COMPANION ANIMAL PARASITICIDES MARKET, BY COUNTRY, 2022–2030
7.2.1 DOGS
7.2.1.1 Dogs accounted for the largest share of the animal parasiticides market for companion animals
TABLE 29 COMPANION ANIMAL PARASITICIDES MARKET FOR DOGS, BY COUNTRY, 2022–2030
7.2.2 CATS
7.2.2.1 High vulnerability to parasitic infections has strengthened product demand in this segment
TABLE 30 COMPANION ANIMAL PARASITICIDES MARKET FOR CATS, BY COUNTRY, 2022–2030
7.2.3 HORSES
7.2.3.1 Rising need for equine parasitic control to drive market growth
TABLE 31 HORSE POPULATION, BY REGION, 2016–2020 (MILLION)
TABLE 32 COMPANION ANIMAL PARASITICIDES MARKET FOR HORSES, BY COUNTRY, 2022–2030
7.2.4 OTHER COMPANION ANIMALS
TABLE 33 OTHER COMPANION ANIMAL PARASITICIDES MARKET, BY COUNTRY, 2022–2030
7.3 LIVESTOCK ANIMALS
FIGURE 42 PRODUCTION OF MEAT WORLDWIDE (2016-2020), BY TYPE
TABLE 34 LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 35 LIVESTOCK ANIMAL PARASITICIDES MARKET, BY COUNTRY,2022–2030
7.3.1 CATTLE
7.3.1.1 Cattle account for the largest share of the food-producinganimals market
TABLE 36 LIVESTOCK ANIMAL PARASITICIDES MARKET FOR CATTLE, BY COUNTRY, 2022–2030
7.3.2 PIGS
7.3.2.1 Growing pork consumption to drive the demand for parasiticides
TABLE 37 LIVESTOCK ANIMAL PARASITICIDES MARKET FOR PIGS, BY COUNTRY, 2022–2030
7.3.3 POULTRY
7.3.3.1 Growing egg consumption in emerging countries to drive the growth of the parasiticides market for poultry
FIGURE 43 LEADING EGG-PRODUCING COUNTRIES WORLDWIDE, 2022
TABLE 38 LIVESTOCK ANIMAL PARASITICIDES MARKET FOR POULTRY, BY COUNTRY, 2022–2030
7.3.4 SHEEP & GOATS
7.3.4.1 Growth in the consumption of sheep and goat meat will support the market
TABLE 39 LIVESTOCK ANIMAL PARASITICIDES MARKET FOR SHEEP & GOATS, BY COUNTRY, 2022–2030
7.3.5 OTHER LIVESTOCK ANIMALS
TABLE 40 OTHER LIVESTOCK ANIMAL PARASITICIDES MARKET, BY COUNTRY, 2022–2030
8 ANIMAL PARASITICIDES MARKET, BY END USER (Page No. - 120)
8.1 INTRODUCTION
TABLE 41 ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
8.2 VETERINARY CLINICS & HOSPITALS
8.2.1 HIGH ADOPTION OF ANIMAL PARASITICIDES IN VETERINARY CLINICS & HOSPITALS TO DRIVE MARKET GROWTH
TABLE 42 ANIMAL PARASITICIDES MARKET FOR VETERINARY CLINICS & HOSPITALS, BY COUNTRY, 2022–2030
8.3 ANIMAL FARMS
8.3.1 INCREASING INCIDENCE OF PARASITIC INFECTIONS IN LIVESTOCK ANIMALS TO SUPPORT MARKET GROWTH
TABLE 43 ANIMAL PARASITICIDES MARKET FOR ANIMAL FARMS, BY COUNTRY, 2022–2030
8.4 HOME CARE SETTINGS
8.4.1 RISING PET OWNERSHIP RATES AND AWARENESS TO DRIVE MARKET GROWTH IN THIS SEGMENT
TABLE 44 ANIMAL PARASITICIDES MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030
9 ANIMAL PARASITICIDES MARKET, BY REGION (Page No. - 125)
9.1 INTRODUCTION
FIGURE 44 ANIMAL PARASITICIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 45 ANIMAL PARASITICIDES MARKET, BY REGION, 2022–2030
9.2 NORTH AMERICA
FIGURE 45 NORTH AMERICA: ANIMAL PARASITICIDES MARKET SNAPSHOT
TABLE 46 NORTH AMERICA: ANIMAL PARASITICIDES MARKET, BY COUNTRY, 2022–2030
TABLE 47 NORTH AMERICA: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 48 NORTH AMERICA: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 49 NORTH AMERICA: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 50 NORTH AMERICA: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 51 NORTH AMERICA: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 52 NORTH AMERICA: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 53 NORTH AMERICA: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.2.1 US
9.2.1.1 Rising pet expenditure and increasing meat consumption are driving the market for animal parasiticides in the US
FIGURE 46 US: PET ADOPTION DURING THE PANDEMIC
FIGURE 47 US: INCREASE IN PET EXPENDITURE, 2011–2022 (USD BILLION)
FIGURE 48 US: BEEF CONSUMPTION, 2011–2020 (BILLION POUNDS)
TABLE 54 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2018 VS. 2022 VS. 2020
TABLE 55 US: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 56 US: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 57 US: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 58 US: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 59 US: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 60 US: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 61 US: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.2.2 CANADA
9.2.2.1 Growing pet adoption rate to drive the market in Canada
TABLE 62 CANADA: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 63 CANADA: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 64 CANADA: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 65 CANADA: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 66 CANADA: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 67 CANADA: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 68 CANADA: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.3 EUROPE
TABLE 69 EUROPE: LIVESTOCK POPULATION, BY TYPE, 2011–2022 (MILLION)
TABLE 70 EUROPE: ANIMAL PARASITICIDES MARKET, BY COUNTRY, 2022–2030
TABLE 71 EUROPE: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 72 EUROPE: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 73 EUROPE: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 74 EUROPE: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 75 EUROPE: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 76 EUROPE: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 77 EUROPE: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.3.1 GERMANY
9.3.1.1 Germany holds the largest share in the European market
TABLE 78 GERMANY: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 79 GERMANY: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 80 GERMANY: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 81 GERMANY: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 82 GERMANY: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 83 GERMANY: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 84 GERMANY: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.3.2 UK
9.3.2.1 Increasing pet ownership is expected to drive market growth in the UK
TABLE 85 UK: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 86 UK: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 87 UK: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 88 UK: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 89 UK: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 90 UK: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 91 UK: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.3.3 FRANCE
9.3.3.1 Presence of major market players to support the growth of the animal parasiticides market in France
TABLE 92 FRANCE: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 93 FRANCE: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 94 FRANCE: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 95 FRANCE: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 96 FRANCE: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 97 FRANCE: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 98 FRANCE: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.3.4 SPAIN
9.3.4.1 Increasing animal health expenditure is expected to drive market growth in Spain
TABLE 99 SPAIN: ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 100 SPAIN: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 101 SPAIN: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 102 SPAIN: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 103 SPAIN: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 104 SPAIN: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 105 SPAIN: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.3.5 ITALY
9.3.5.1 Need to curb zoonotic diseases in livestock will contribute to the demand for animal parasiticides in Italy
TABLE 106 ITALY: ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 107 ITALY: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 108 ITALY: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 109 ITALY: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 110 ITALY: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 111 ITALY: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 112 ITALY: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.3.6 REST OF EUROPE
FIGURE 49 NETHERLANDS: NUMBER OF DAIRY COWS, 2011-2020 (THOUSAND)
TABLE 113 ROE: COMPANION ANIMAL OWNERSHIP, BY COUNTRY, 2020 (MILLION)
TABLE 114 ROE: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 115 ROE: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 116 ROE: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 117 ROE: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 118 ROE: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 119 ROE: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 120 ROE: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.4 ASIA PACIFIC
FIGURE 50 ASIA PACIFIC: ANIMAL PARASITICIDES MARKET SNAPSHOT
TABLE 121 ASIA PACIFIC: ANIMAL PARASITICIDES MARKET, BY COUNTRY, 2022–2030
TABLE 122 ASIA PACIFIC: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 123 ASIA PACIFIC: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 124 ASIA PACIFIC: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 125 ASIA PACIFIC: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 126 ASIA PACIFIC: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 127 ASIA PACIFIC: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 128 ASIA PACIFIC: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.4.1 CHINA
9.4.1.1 China dominates the APAC animal parasiticides market
FIGURE 51 CHINA: INCREASING CONSUMPTION OF PORK PRODUCTS, PER CAPITA (KILOGRAMS) (2011–2020)
TABLE 129 CHINA: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 130 CHINA: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 131 CHINA: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 132 CHINA: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 133 CHINA: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 134 CHINA: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 135 CHINA: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.4.2 AUSTRALIA
9.4.2.1 Rising awareness and increasing pet population are supporting the demand for parasiticides in Australia
TABLE 136 AUSTRALIA: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 137 AUSTRALIA: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 138 AUSTRALIA: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 139 AUSTRALIA: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 140 AUSTRALIA: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 141 AUSTRALIA: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 142 AUSTRALIA: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.4.3 JAPAN
9.4.3.1 Rising demand for imported breeds is driving pet adoption in the country
TABLE 143 JAPAN: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 144 JAPAN: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 145 JAPAN: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 146 JAPAN: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE,2022–2030
TABLE 147 JAPAN: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 148 JAPAN: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 149 JAPAN: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.4.4 INDIA
9.4.4.1 Increasing livestock population is contributing to market growth in India
TABLE 150 INDIA: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 151 INDIA: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 152 INDIA: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 153 INDIA: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 154 INDIA: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 155 INDIA: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 156 INDIA: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.4.5 REST OF ASIA PACIFIC
TABLE 157 ROAPAC: ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 158 ROAPAC: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 159 ROAPAC: ENDOPARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 160 ROAPAC: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 161 ROAPAC: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 162 ROAPAC: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 163 ROAPAC: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.5 LATIN AMERICA
TABLE 164 LATIN AMERICA: ANIMAL PARASITICIDES MARKET, BY COUNTRY, 2022–2030
TABLE 165 LATIN AMERICA: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 166 LATIN AMERICA: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 167 LATIN AMERICA: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 168 LATIN AMERICA: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 169 LATIN AMERICA: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 170 LATIN AMERICA: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 171 LATIN AMERICA: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.5.1 BRAZIL
9.5.1.1 Growing pet adoption and rising awareness about animal health to drive market growth
TABLE 172 BRAZIL: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 173 BRAZIL: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 174 BRAZIL: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 175 BRAZIL: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 176 BRAZIL: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 177 BRAZIL: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 178 BRAZIL: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.5.2 REST OF LATIN AMERICA
TABLE 179 ROLATAM: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 180 ROLATAM: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 181 ROLATAM: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 182 ROLATAM: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 183 ROLATAM: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE,2022–2030
TABLE 184 ROLATAM: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 185 ROLATAM: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.6 MIDDLE EAST AND AFRICA
TABLE 186 MIDDLE EAST AND AFRICA: ANIMAL PARASITICIDES MARKET, BY COUNTRY, 2022–2030
TABLE 187 MIDDLE EAST & AFRICA: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 188 MIDDLE EAST & AFRICA: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 189 MIDDLE EAST & AFRICA: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 190 MIDDLE EAST & AFRICA: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 191 MIDDLE EAST & AFRICA: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 192 MIDDLE EAST & AFRICA: LIVESTOCK ANIMAL PARASITICIDES MARKET,BY TYPE, 2022–2030
TABLE 193 MIDDLE EAST & AFRICA: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.6.1 TURKEY
9.6.1.1 Rising meat production in Turkey is expected to drive the growth of the animal parasiticides market
TABLE 194 TURKEY: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 195 TURKEY: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 196 TURKEY: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 197 TURKEY: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 198 TURKEY: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 199 TURKEY: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 200 TURKEY: ANIMAL PARASITICIDES MARKET, BY END USER, 2022–2030
9.6.2 REST OF THE MIDDLE EAST AND AFRICA
TABLE 201 ROMEA: ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 202 ROMEA: ECTOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 203 ROMEA: ENDOPARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 204 ROMEA: ANIMAL PARASITICIDES MARKET, BY ANIMAL TYPE, 2022–2030
TABLE 205 ROMEA: COMPANION ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 206 ROMEA: LIVESTOCK ANIMAL PARASITICIDES MARKET, BY TYPE, 2022–2030
TABLE 207 ROMEA: ANIMAL PARASITICIDES MARKET, BY END USER,2022–2030
10 COMPETITIVE LANDSCAPE (Page No. - 196)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 52 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE ANIMAL PARASITICIDES MARKET
10.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE ANIMAL PARASITICIDES MARKET
FIGURE 53 REVENUE ANALYSIS FOR THE KEY PLAYERS IN THE ANIMAL PARASITICIDES MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 54 ANIMAL PARASITICIDES MARKET SHARE ANALYSIS, BY KEY PLAYER (2020)
TABLE 208 ANIMAL PARASITICIDES MARKET: DEGREE OF COMPETITION
10.5 R&D ASSESSMENT OF KEY PLAYERS
10.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS
10.7 PRODUCT PORTFOLIO ANALYSIS
10.8 COMPANY EVALUATION QUADRANT
FIGURE 55 ANIMAL PARASITICIDES MARKET: COMPANY EVALUATION MATRIX, 2020
10.8.1 STARS
10.8.2 PERVASIVE PLAYERS
10.8.3 EMERGING LEADERS
10.8.4 PARTICIPANTS
10.9 COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS
FIGURE 56 ANIMAL PARASITICIDES MARKET: COMPANY EVALUATION MATRIX FOR SMES & START-UPS
10.9.1 PROGRESSIVE COMPANIES
10.9.2 DYNAMIC COMPANIES
10.9.3 STARTING BLOCKS
10.9.4 RESPONSIVE COMPANIES
10.1 COMPETITIVE BENCHMARKING
10.11 COMPETITIVE SCENARIO
10.11.1 PRODUCT LAUNCHES & APPROVALS
10.11.2 DEALS
10.11.3 EXPANSIONS
11 COMPANY PROFILES (Page No. - 216)
11.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 ELANCO ANIMAL HEALTH INCORPORATED
TABLE 217 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW
FIGURE 57 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2020)
11.1.2 BOEHRINGER INGELHEIM GMBH
FIGURE 58 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2020)
11.1.3 ZOETIS INC.
TABLE 219 ZOETIS INC.: BUSINESS OVERVIEW
FIGURE 59 ZOETIS INC.: COMPANY SNAPSHOT (2020)
11.1.4 MERCK & CO., INC
TABLE 220 MERCK & CO., INC.: BUSINESS OVERVIEW
FIGURE 60 MERCK & CO., INC.: COMPANY SNAPSHOT (2020)
11.1.5 VIRBAC
TABLE 221 VIRBAC: BUSINESS OVERVIEW
FIGURE 61 VIRBAC: COMPANY SNAPSHOT (2020)
11.1.6 VETOQUINOL S.A.
TABLE 222 VETOQUINOL S.A.: BUSINESS OVERVIEW
FIGURE 62 VETOQUINOL S.A.: COMPANY SNAPSHOT (2020)
11.1.7 PETIQ, LLC
TABLE 223 PETIQ, LLC: BUSINESS OVERVIEW
FIGURE 63 PETIQ, LLC: COMPANY SNAPSHOT (2020)
11.1.8 SEQUENT SCIENTIFIC LIMITED
TABLE 224 SEQUENT SCIENTIFIC LIMITED: BUSINESS OVERVIEW
FIGURE 64 SEQUENT SCIENTIFIC LIMITED: COMPANY SNAPSHOT (2020)
11.1.9 KRKA GROUP
TABLE 225 KRKA GROUP: BUSINESS OVERVIEW
FIGURE 65 KRKA GROUP: COMPANY SNAPSHOT (2020)
11.1.10 ECO ANIMAL HEALTH GROUP PLC
TABLE 226 ECO ANIMAL HEALTH GROUP PLC: BUSINESS OVERVIEW
FIGURE 66 ECO ANIMAL HEALTH GROUP PLC: COMPANY SNAPSHOT (2020)
11.1.11 CEVA SANTÉ ANIMALE
TABLE 227 CEVA SANTÉ ANIMALE: BUSINESS OVERVIEW
11.1.12 CHANELLE PHARMA
TABLE 228 CHANELLE PHARMA: BUSINESS OVERVIEW
11.1.13 BIMEDA ANIMAL HEALTH
TABLE 229 BIMEDA ANIMAL HEALTH: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 NORBROOK
TABLE 230 NORBROOK: BUSINESS OVERVIEW
11.2.2 KYORITSU SEIYAKU CORPORATION
TABLE 231 KYORITSU SEIYAKU CORPORATION: BUSINESS OVERVIEW
11.2.3 SMARTVET HOLDINGS, INC.
TABLE 232 SMARTVET HOLDINGS: BUSINESS OVERVIEW
11.2.4 UCBVET
TABLE 233 UCBVET: BUSINESS OVERVIEW
11.2.5 CALIER
TABLE 234 CALIER: BUSINESS OVERVIEW
11.2.6 ABBEY ANIMAL HEALTH PTY LTD.
TABLE 235 ABBEY ANIMAL HEALTH PTY LTD.: BUSINESS OVERVIEW
11.2.7 BIOGÉNESIS BAGÓ
TABLE 236 BIOGÉNESIS BAGÓ: BUSINESS OVERVIEW
11.2.8 PRN PHARMACAL
TABLE 237 PRN PHARMACAL: BUSINESS OVERVIEW
11.2.9 LUTIM PHARMA PRIVATE LIMITED
11.2.10 VETANCO SA
11.2.11 BRILLIANT BIO PHARMA
11.2.12 INOVET
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 270)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers